Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Charles River Laboratories (CRL) advanced following a strong earnings report and an increase to full-year guidance. Results reflected improving...
— John W. Rogers, Jr.
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. ($CRL), representing 3.4% of the composite, provides early-stage contract research services, animal models, and clinical discovery support for global pharmaceutical and biotechnology corporations. Ariel maintains a...
Charles River Laboratories ($CRL), which represents 3.9% of the fund's portfolio, is an essential contract research organization providing discovery and safety assessment services, laboratory products, and manufacturing support to the global biopharmaceutical industry. The manager holds...
Our investments in drug development companies like Charles River Labs (CRL) and Medpace Holdings (MEDP) pulled back, driven by AI disruption fears.
More institutional theses from Ariel Fund
Zebra Technologies ($ZBRA) manufactures enterprise barcode scanners, mobile computing devices, and RFID tracking solutions that automate enterprise workflows, representing 5.0% of the portfolio. The manager maintains...
Midera Food Processing, Inc. ($MFP) represents 0.0% of the fund's portfolio following a complete post-spinoff liquidation to redeploy capital into higher-conviction names.
Bio-Rad Laboratories ($BIO) develops, manufactures, and markets clinical diagnostics instruments and life sciences laboratory research systems, constituting 4.6% of the fund. The manager takes...